hepatitis b/gin diare

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 21 rezilta yo

Evaluation the Palliative Effects of Colchicine on Primary Hepatic Malignant Tumors Unable to Receive Curative Treatment

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study procedures 1. Written informed consent before study specific procedures are undertaken. The investigators will explain the contents of the trial especially the information about the possible side effects, other alternative treatment and the right to withdraw based on the participant own

Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Randomized, open-label, parallel-group, multicenter, phase III trial with two arms, one with acalabrutinib (Arm A) and the other with the standard of care for the management of early Binet stage A patients "clinical observation (watch & wait)" (Arm B) in patients with untreated early stage CLL and

Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study design: Prospective controlled study experimental comparative Study duration: 1 year The number of patients to enroll: 20 patients. After being randomized, selected patients who meet the criteria for inclusion and exclusion will be assigned 1:1 in two groups. A group will start treatment with

YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

HCC patients with chronic HBV (+) (HBsAg(+) and IgM anti-HBc (-)), and Child-Pugh A status will be randomized to either the study arm (YIV-906 plus sorafenib) or control arm (placebo plus sorafenib) at ratio of 2:1. Patients will be stratified according to metastatic status (extrahepatic/vascular

Clinical Study on Combined Immune Effect of EV71 Inactivated Vaccine

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study design and participants The study was conducted in four provinces (Shandong, Shanxi, Shaanxi and Hunan) of China, which contains Haiyang city, Rushan city, Shimen County, Chen Cang District, Qishan County, Taigu County and Qi County. 6/8 months children were recruited in this study,

Add-on Methotrexate for the Treatment of Schizophrenia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVES The objective of the study is to evaluate the efficacy of Methotrexate compared to placebo, as add-on to anti-psychotics in the treatment of patients with schizophrenia or schizoaffective disorder. ENDPOINTS Primary outcome measure: PANSS positive score at the end of the trial. Secondary

Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Study design and participants The study was conducted in three counties (Yucheng, Xintai and Dongchangfu) of Shandong province, China, which had the highest reported HCV case numbers in the province. Potential patients with chronic HCV infection were recruited by checking the medical records of the

Emtricitabine/Tenofovir Alafenamide as Salvage ART

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Despite the success of antiretroviral therapy (ART), a subset of HIV-1-infected patients have uncontrolled viremia, multiple drug class resistance, and limited treatment options. Tenofovir disoproxil fumarate (TDF) forms part of most ART regimens, however its long-term use is associated with renal

Comparison of Bovine Colostrum Versus Placebo in Treatment of Severe Alcoholic Hepatitis: A Randomized Double Blind Controlled Trial

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Diagnosis: The diagnosis of Alcoholic hepatitis is made by the following criteria (12) I. Chronic active alcohol abuse - >80 grams in males and > 60 grams in females for > 5 years for developing Alcoholic Cirrhosis (13) Alcohol use will be evaluated with the AUDIT score (EASL guidelines (14) II.

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The Philadelphia chromosome-negative chronic myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell malignancies that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). PV and ET can evolve into myelofibrosis, termed post PV/ET MF.

Efficacy of Combination Therapy of Glucocorticoids and Bovine Colostrum in Treatment of Severe Alcoholic Hepatitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Severe alcoholic hepatitis is associated with significant morbidity and mortality. Diagnosis: The diagnosis of (AH) is made by the following criteria11 I.Chronic active alcohol abuse - > 80 grams in males and > 20 grams in females. II. Duration of jaundice < 3 months III. Serum Bilirubin >5 mg/dl

Reduction of C-Difficile Infection Using Stool Transplant

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Background Clostridium-difficile (C-difficile) is a gram positive anaerobic spore-forming bacterium that can lead to severe diarrhea and pseudomembranous colitis. According to Schroeder (2005), there are approximately 3 million cases annually with a mortality rate of 1-2.5 %. It is most often

Efficacy and Safety of Fecal Microbiota Transplantation for Severe Clostridium Difficile Associated Colitis

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Screening and Consent - Index cases: 1. Hospitalized patient with the diagnosis of severe CDAD 2. At screening visit the study investigator(s) will explain the study in detail, answer any questions the candidate may have, and give the candidate a consent form to read and sign. 3. After signing the

Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Dosing schedule: 2 tablets (1 mg) three times per day (after breakfast, lunch and dinner); continue 4 days and stop for 3 days (1 cycle) Adjustment the dosage of colchicine during study: 1. The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child

L-ornithine L-aspartate in Overt Hepatic Encephalopathy

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A. Introduction and Review of literature Hepatic encephalopathy (HE) is broadly defined as an alteration in mental status and cognitive function occurring in presence of liver failure. The clinical picture of HE arises as a complication of chronic and, more rarely, acute liver disease. HE occurs in

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye